Skip to content

Harmony Biosciences Holdings, Inc.

HRMY· NasdaqCore metricsCIK 1802665

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -1.24%
Market cap
$1.99B
58.72M shares
Filings
461
$268.92M
Q3 2026+21.5% FY25 yoy
$48.20M
Q3 2026+9.1% FY25 yoy
$54.20M
Q3 2026+9.2% FY25 yoy
$347.89M
FY 2025derived+59.1% FY25 yoy
$0.81
Q3 2026+8.0% FY25 yoy
$647.10M
Q3 2026+66.1% FY25 yoy
$1.99B
11.1×
2.0×
1.9×
—
—

Twelve months to Sep 30, 2026 · derived

Price

$33.81+2.53%+$0.84past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$868.45MFY 2025
$868.45M0FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$868,453,000reported
FY 20242024-12-31$714,734,000reported
FY 20232023-12-31$582,022,000reported
FY 20222022-12-31$437,855,000reported
FY 20212021-12-31$305,440,000reported
FY 20202020-12-31$159,742,000reported
FY 20192019-12-31$5,995,000reported

Capital returns

Dividends and buybacks · FY2020 to FY2023
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2023—$100.00M$100.00M—56.77M sh−4.8%45.6%
FY2020—$167.00K$167.00K—56.89M sh+630.6%—

Pharmaceutical preparations

Harmony Biosciences Holdings, Inc. is the 39th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Harmony Biosciences Holdings, Inc. · CIK 1802665 · Engraved from SEC EDGAR